AstraZeneca has carved off six inflammation and autoimmune assets to create a new biotech, Viela Bio. The startup put together a $250 million series A round and a management team from its parent company to guide the mix of clinical and preclinical programs forward.
{iframe}https://www.fiercebiotech.com/biotech/astrazeneca-spinout-bags-250m-pipeline-headed-by-late-phase-autoimmune-drug{/iframe}